
ENERGENESIS — Investor Relations & Filings
Energenesis Biomedical Co., Ltd. specializes in the research and development of innovative pharmaceuticals through its proprietary ENERGI drug development platform. The company focuses on the activation of AMP-activated protein kinase (AMPK), a critical enzyme for cellular energy regulation, to develop therapeutic solutions for various diseases. Its core pipeline centers on small molecule purine compounds designed to modulate cellular energy metabolism. Operating with an intellectual property-driven strategy, the company manages the development cycle from early-stage drug discovery through clinical trial validation. Energenesis Biomedical aims to increase the value of its proprietary technologies for strategic out-licensing and collaboration with global pharmaceutical partners. In addition to drug development, the company offers specialized testing and analysis services and distributes research reagents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 114年度股利金額(董事會決議) | 2026-05-22 | Chinese | |
| 115年第1季財務報告書 — 202601_6657_AI1.pdf | 2026-05-13 | Chinese | |
| 115年第1季海外子公司投資 | 2026-05-11 | Chinese | |
| 115年第1季權益變動表 | 2026-05-11 | Chinese | |
| 115年第1季現金流量表 | 2026-05-11 | Chinese | |
| 115年第1季綜合損益表 | 2026-05-11 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46778242 | 114年度股利金額(董事會決議) | 2026-05-22 | Chinese | ||
| 46338951 | 115年第1季財務報告書 — 202601_6657_AI1.pdf | 2026-05-13 | Chinese | ||
| 45740777 | 115年第1季海外子公司投資 | 2026-05-11 | Chinese | ||
| 45746274 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45741609 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741439 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45741235 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
| 39978408 | 114年第4季財務報告書 — 202502_6657_AIA.pdf | 2026-04-30 | English | ||
| 39871803 | 114年第4季財務報告書 — 202501_6657_AIA.pdf | 2026-04-30 | English | ||
| 39871783 | 114年第4季財務報告書 — 202501_6657_AI1.pdf | 2026-04-30 | Chinese | ||
| 39886223 | 114年第4季財務報告書 — 202504_6657_AIC.pdf | 2026-04-30 | English | ||
| 39886197 | 114年第4季財務報告書 — 202504_6657_AIA.pdf | 2026-04-30 | English | ||
| 39886176 | 114年第4季財務報告書 — 202504_6657_AI3.pdf | 2026-04-30 | Chinese | ||
| 39886119 | 114年第4季財務報告書 — 202504_6657_AI1.pdf | 2026-04-30 | Chinese | ||
| 39886095 | 114年第4季財務報告書 — 202503_6657_AIA.pdf | 2026-04-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Hoth Therapeutics, Inc.
A clinical-stage biopharma company advancing drugs for unme…
|
HOTH | US | Professional, scientific and te… |
|
Human Stem Cells Institute PJSC
Develops gene therapies, vaccines, medical devices, and gen…
|
ISKJ | RU | Professional, scientific and te… |
|
HVIVO PLC
A contract research organization specializing in human chal…
|
HVO | GB | Professional, scientific and te… |
|
Hybrigenics SA
Provider of technologies for studying molecular interaction…
|
ALHYG | FR | Professional, scientific and te… |
|
Hyundai ADM Bio lnc.
A contract research organization providing clinical trial s…
|
187660 | KR | Professional, scientific and te… |
|
HYUNDAI BIOSCIENCE CO., LTD.
Develops antiviral and anticancer drugs using a proprietary…
|
048410 | KR | Professional, scientific and te… |
|
IATRA Life Sciences Corporation
Develops and commercializes unique technologies in diagnost…
|
IAT-H | CA | Professional, scientific and te… |
|
ICON PLC
Global provider of outsourced development services for phar…
|
ICLR | IE | Professional, scientific and te… |
|
IGC Pharma, Inc.
Clinical-stage biotech firm developing AI-driven treatments…
|
IGC | US | Professional, scientific and te… |
|
IMAGION BIOSYSTEMS LIMITED
Develops nanoparticle-based imaging for non-invasive cancer…
|
IBX | AU | Professional, scientific and te… |
ENERGENESIS via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52601/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52601 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52601 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52601 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52601}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ENERGENESIS (id: 52601)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.